CAFERGOT by Novartis is clinical pharmacology ergotamine is an alpha adrenergic blocking agent with a direct stimulating effect on the smooth muscle of peripheral and cranial blood vessels and produces depression of central vasomotor centers. First approved in 1948.
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
CAFERGOT is an oral tablet combining ergotamine (an alpha-adrenergic blocker and serotonin antagonist) with caffeine for acute migraine treatment. Ergotamine directly stimulates cranial blood vessel smooth muscle and depresses central vasomotor centers, while caffeine enhances the vasoconstrictive effect. It is indicated for patients experiencing migraine attacks, particularly those with nausea/vomiting who cannot tolerate oral medication.
Legacy product approaching loss of exclusivity with minimal market presence; brand support likely focused on maintenance rather than growth.
CLINICAL PHARMACOLOGY Ergotamine is an alpha adrenergic blocking agent with a direct stimulating effect on the smooth muscle of peripheral and cranial blood vessels and produces depression of central vasomotor centers. The compound also has the properties of serotonin antagonism. In comparison to…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on CAFERGOT at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
CAFERGOT offers minimal career growth potential due to its legacy status, low market activity (0 linked jobs), and approaching loss of exclusivity. Career roles are typically maintenance-focused in small commercial teams supporting an established, declining franchise.